[
    {
      "FIELD1": 0,
      "FIELD2": 0,
      "Gene name": "RB1",
      "Genomic Position": "13:48877911-49056122(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Alpelisib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:25002028"
    },
    {
      "FIELD1": 1,
      "FIELD2": 1,
      "Gene name": "RB1",
      "Genomic Position": "13:48877911-49056122(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Alpelisib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:25002028"
    },
    {
      "FIELD1": 2,
      "FIELD2": 2,
      "Gene name": "RB1",
      "Genomic Position": "13:48877911-49056122(+)",
      "CDS Mutation": "PHOSPHORYLATION",
      "AA Mutation": "p.PHOSPHORYLATION",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Resistance",
      "Therapies": "Alpelisib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:25002028"
    },
    {
      "FIELD1": 3,
      "FIELD2": 3,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified_and_ERBB2_unspecified",
      "AA Mutation": "unspecified_and_ERBB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 4,
      "FIELD2": 4,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified_or_BRCA2_unspecified",
      "AA Mutation": "unspecified_or_BRCA2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 5,
      "FIELD2": 5,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Triple-receptor Negative Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 6,
      "FIELD2": 6,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified_or_BRCA2_unspecified",
      "AA Mutation": "unspecified_or_BRCA2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 7,
      "FIELD2": 7,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified_or_BRCA2_unspecified",
      "AA Mutation": "unspecified_or_BRCA2_unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 8,
      "FIELD2": 8,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
      "AA Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 9,
      "FIELD2": 9,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
      "AA Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 10,
      "FIELD2": 10,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
      "AA Mutation": "unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 11,
      "FIELD2": 11,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 12,
      "FIELD2": 12,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Her2-receptor Negative Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 13,
      "FIELD2": 13,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "Loss-of-function",
      "AA Mutation": "Loss-of-function",
      "Disease": "Her2-receptor Negative Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 14,
      "FIELD2": 14,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "Loss-of-function",
      "AA Mutation": "Loss-of-function",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 15,
      "FIELD2": 15,
      "Gene name": "BRCA1",
      "Genomic Position": "17:41197646-41277500(-)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Triple-receptor Negative Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Resistance",
      "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05485766"
    },
    {
      "FIELD1": 16,
      "FIELD2": 16,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "Amplification",
      "AA Mutation": "Amplification",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 17,
      "FIELD2": 17,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 18,
      "FIELD2": 18,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_WT1_unspecified",
      "AA Mutation": "unspecified_and_WT1_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 19,
      "FIELD2": 19,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)_",
      "AA Mutation": "unspecified_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)_",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 20,
      "FIELD2": 20,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_ESR1_unspecified",
      "AA Mutation": "unspecified_and_ESR1_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 21,
      "FIELD2": 21,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_GATA3_unspecified",
      "AA Mutation": "unspecified_and_GATA3_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 22,
      "FIELD2": 22,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_PIK3CA_unspecified",
      "AA Mutation": "unspecified_and_PIK3CA_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 23,
      "FIELD2": 23,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_PTEN_unspecified",
      "AA Mutation": "unspecified_and_PTEN_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 24,
      "FIELD2": 24,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_TBX3_unspecified",
      "AA Mutation": "unspecified_and_TBX3_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 25,
      "FIELD2": 25,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_TOP2A_unspecified",
      "AA Mutation": "unspecified_and_TOP2A_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 26,
      "FIELD2": 26,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_TP53_unspecified",
      "AA Mutation": "unspecified_and_TP53_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 27,
      "FIELD2": 27,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_TP53_unspecified_",
      "AA Mutation": "unspecified_and_TP53_unspecified_",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 28,
      "FIELD2": 28,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "Overexpression",
      "AA Mutation": "Overexpression",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 29,
      "FIELD2": 29,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "SERUM_LEVELS",
      "AA Mutation": "SERUM_LEVELS",
      "Disease": "Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 30,
      "FIELD2": 30,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_ERBB2_unspecified",
      "AA Mutation": "unspecified_and_ERBB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 31,
      "FIELD2": 31,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "Exon19,Exon20",
      "AA Mutation": "Exon19,Exon20",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 32,
      "FIELD2": 32,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 2,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 33,
      "FIELD2": 33,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 34,
      "FIELD2": 34,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "Amplification",
      "AA Mutation": "Amplification",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 35,
      "FIELD2": 35,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 36,
      "FIELD2": 36,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_NRG1_unspecified",
      "AA Mutation": "unspecified_and_NRG1_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 37,
      "FIELD2": 37,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_ERBB3_unspecified",
      "AA Mutation": "unspecified_and_ERBB3_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 38,
      "FIELD2": 38,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified_and_PIK3CA_unspecified",
      "AA Mutation": "unspecified_and_PIK3CA_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 39,
      "FIELD2": 39,
      "Gene name": "ERBB2",
      "Genomic Position": "17:37856333-37884915(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma in situ / ductal carcinoma in situ",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "H2NVAC + Sargramostim",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04144023"
    },
    {
      "FIELD1": 40,
      "FIELD2": 40,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 41,
      "FIELD2": 41,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 42,
      "FIELD2": 42,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "unspecified_or_PTEN_unspecified_or_TP53_unspecified",
      "AA Mutation": "unspecified_or_PTEN_unspecified_or_TP53_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 43,
      "FIELD2": 43,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 44,
      "FIELD2": 44,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "c.3140A>G",
      "AA Mutation": "p.H1047R",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": 121913279,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 45,
      "FIELD2": 45,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 46,
      "FIELD2": 46,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 47,
      "FIELD2": 47,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "c.1634A>G",
      "AA Mutation": "p.E545",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": 121913274,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 48,
      "FIELD2": 48,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "H1047X",
      "AA Mutation": "p.H1047X",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 49,
      "FIELD2": 49,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "c.1624G>A",
      "AA Mutation": "p.E542K",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": 121913273,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 50,
      "FIELD2": 50,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "unspecified_or_PTEN_unspecified",
      "AA Mutation": "unspecified_or_PTEN_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 51,
      "FIELD2": 51,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 52,
      "FIELD2": 52,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 53,
      "FIELD2": 53,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "Exon9_or_PIK3CA_Exon20",
      "AA Mutation": "Exon9_or_PIK3CA_Exon20",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 54,
      "FIELD2": 54,
      "Gene name": "PIK3CA",
      "Genomic Position": "3:178866311-178957881(+)",
      "CDS Mutation": "c.3140A>G",
      "AA Mutation": "p.H1047R",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 4,
      "Response to Drug": "Sensitivity",
      "Therapies": "Fulvestrant,Everolimus",
      "Description": "",
      "rs value": 121913279,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 55,
      "FIELD2": 55,
      "Gene name": "AKT2",
      "Genomic Position": "19:40736224-40791302(-)",
      "CDS Mutation": "EXPRESSION",
      "AA Mutation": "EXPRESSION",
      "Disease": "Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Trastuzumab",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:22842582"
    },
    {
      "FIELD1": 56,
      "FIELD2": 56,
      "Gene name": "IGF1R",
      "Genomic Position": "15:99192200-99507759(+)",
      "CDS Mutation": "Overexpression",
      "AA Mutation": "Overexpression",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Metformin,Exemestane",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:26706833"
    },
    {
      "FIELD1": 57,
      "FIELD2": 57,
      "Gene name": "TP53",
      "Genomic Position": "17:7571720-7590856(-)",
      "CDS Mutation": "c.745A>T",
      "AA Mutation": "p.R249",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Tamoxifen",
      "Description": "",
      "rs value": 587782082,
      "pmid": "PubMed:10786679"
    },
    {
      "FIELD1": 58,
      "FIELD2": 58,
      "Gene name": "TP53",
      "Genomic Position": "17:7571720-7590856(-)",
      "CDS Mutation": "DNA_Binding_Domain_Mutation",
      "AA Mutation": "DNA_Binding_Domain_Mutation",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Resistance",
      "Therapies": "Tamoxifen",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:10786679"
    },
    {
      "FIELD1": 59,
      "FIELD2": 59,
      "Gene name": "TP53",
      "Genomic Position": "17:7571720-7590856(-)",
      "CDS Mutation": "deletion_and_PDCD4_unspecified",
      "AA Mutation": "deletion_and_PDCD4_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Tamoxifen",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:10786679"
    },
    {
      "FIELD1": 60,
      "FIELD2": 60,
      "Gene name": "TP53",
      "Genomic Position": "17:7571720-7590856(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Tamoxifen",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:10786679"
    },
    {
      "FIELD1": 61,
      "FIELD2": 61,
      "Gene name": "TP53",
      "Genomic Position": "17:7571720-7590856(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Tamoxifen",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:10786679"
    },
    {
      "FIELD1": 62,
      "FIELD2": 62,
      "Gene name": "TP53",
      "Genomic Position": "17:7571720-7590856(-)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Breast Cancer",
      "therapy_rank": 4,
      "Response to Drug": "Resistance",
      "Therapies": "Tamoxifen",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:10786679"
    },
    {
      "FIELD1": 63,
      "FIELD2": 63,
      "Gene name": "FGFR1",
      "Genomic Position": "8:38268656-38325363(-)",
      "CDS Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
      "AA Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "FGFR Inhibitor AZD4547",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27179038"
    },
    {
      "FIELD1": 64,
      "FIELD2": 64,
      "Gene name": "FGFR1",
      "Genomic Position": "8:38268656-38325363(-)",
      "CDS Mutation": "Amplification",
      "AA Mutation": "Amplification",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "FGFR Inhibitor AZD4547",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27179038"
    },
    {
      "FIELD1": 65,
      "FIELD2": 65,
      "Gene name": "FGFR1",
      "Genomic Position": "8:38268656-38325363(-)",
      "CDS Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
      "AA Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "FGFR Inhibitor AZD4547",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27179038"
    },
    {
      "FIELD1": 66,
      "FIELD2": 66,
      "Gene name": "FGFR1",
      "Genomic Position": "8:38268656-38325363(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "FGFR Inhibitor AZD4547",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27179038"
    },
    {
      "FIELD1": 67,
      "FIELD2": 67,
      "Gene name": "FGFR1",
      "Genomic Position": "8:38268656-38325363(-)",
      "CDS Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
      "AA Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "FGFR Inhibitor AZD4547",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27179038"
    },
    {
      "FIELD1": 68,
      "FIELD2": 68,
      "Gene name": "FGFR1",
      "Genomic Position": "8:38268656-38325363(-)",
      "CDS Mutation": "Amplification",
      "AA Mutation": "Amplification",
      "Disease": "Breast Cancer",
      "therapy_rank": 4,
      "Response to Drug": "Sensitivity",
      "Therapies": "FGFR Inhibitor AZD4547",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27179038"
    },
    {
      "FIELD1": 69,
      "FIELD2": 69,
      "Gene name": "ESR1",
      "Genomic Position": "6:152011631-152424409(+)",
      "CDS Mutation": "Overexpression",
      "AA Mutation": "Overexpression",
      "Disease": "Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Endocrine therapy",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:24217577"
    },
    {
      "FIELD1": 70,
      "FIELD2": 70,
      "Gene name": "ESR1",
      "Genomic Position": "6:152011631-152424409(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Endocrine therapy",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:24217577"
    },
    {
      "FIELD1": 71,
      "FIELD2": 71,
      "Gene name": "ESR1",
      "Genomic Position": "6:152011631-152424409(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / ER-positive carcinoma",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Endocrine therapy",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:24217577"
    },
    {
      "FIELD1": 72,
      "FIELD2": 72,
      "Gene name": "ESR1",
      "Genomic Position": "6:152011631-152424409(+)",
      "CDS Mutation": "c.851-26475A>G",
      "AA Mutation": "p.?",
      "Disease": "ductal_carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Endocrine therapy",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:24217577"
    },
    {
      "FIELD1": 73,
      "FIELD2": 73,
      "Gene name": "ESR1",
      "Genomic Position": "6:152011631-152424409(+)",
      "CDS Mutation": "c.1613A>G",
      "AA Mutation": "p.D538G",
      "Disease": "ductal_carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Endocrine therapy",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:24217577"
    },
    {
      "FIELD1": 74,
      "FIELD2": 74,
      "Gene name": "ESR1",
      "Genomic Position": "6:152011631-152424409(+)",
      "CDS Mutation": "c.830A>G",
      "AA Mutation": "p.D277G",
      "Disease": "ductal_carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Endocrine therapy",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:24217577"
    },
    {
      "FIELD1": 75,
      "FIELD2": 75,
      "Gene name": "ESR1",
      "Genomic Position": "6:152011631-152424409(+)",
      "CDS Mutation": "c.*488A>G",
      "AA Mutation": "p.?",
      "Disease": "ductal_carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Endocrine therapy",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:24217577"
    },
    {
      "FIELD1": 76,
      "FIELD2": 76,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "Loss",
      "AA Mutation": "Loss",
      "Disease": "Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 77,
      "FIELD2": 77,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 78,
      "FIELD2": 78,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 79,
      "FIELD2": 79,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "Loss",
      "AA Mutation": "Loss",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Resistance",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 80,
      "FIELD2": 80,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "Expression",
      "AA Mutation": "Expression",
      "Disease": "Breast Cancer",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 81,
      "FIELD2": 81,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 82,
      "FIELD2": 82,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "Loss",
      "AA Mutation": "Loss",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 83,
      "FIELD2": 83,
      "Gene name": "PTEN",
      "Genomic Position": "10:89622870-89731687(+)",
      "CDS Mutation": "Expression",
      "AA Mutation": "Expression",
      "Disease": "Her2-receptor Positive Breast Cancer",
      "therapy_rank": 4,
      "Response to Drug": "Resistance",
      "Therapies": "Everolimus,Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:27445490"
    },
    {
      "FIELD1": 84,
      "FIELD2": 84,
      "Gene name": "AKT1",
      "Genomic Position": "14:105235686-105260461(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capivasertib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:26351323"
    },
    {
      "FIELD1": 85,
      "FIELD2": 85,
      "Gene name": "AKT1",
      "Genomic Position": "14:105235686-105260461(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capivasertib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:26351323"
    },
    {
      "FIELD1": 86,
      "FIELD2": 86,
      "Gene name": "AKT1",
      "Genomic Position": "14:105235686-105260461(-)",
      "CDS Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
      "AA Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capivasertib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:26351323"
    },
    {
      "FIELD1": 87,
      "FIELD2": 87,
      "Gene name": "AKT1",
      "Genomic Position": "14:105235686-105260461(-)",
      "CDS Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
      "AA Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capivasertib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:26351323"
    },
    {
      "FIELD1": 88,
      "FIELD2": 88,
      "Gene name": "AKT1",
      "Genomic Position": "14:105235686-105260461(-)",
      "CDS Mutation": "c.49G>A",
      "AA Mutation": "p.E17K",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capivasertib",
      "Description": "",
      "rs value": 121434592,
      "pmid": "PubMed:26351323"
    },
    {
      "FIELD1": 89,
      "FIELD2": 89,
      "Gene name": "AKT1",
      "Genomic Position": "14:105235686-105260461(-)",
      "CDS Mutation": "unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
      "AA Mutation": "unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capivasertib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:26351323"
    },
    {
      "FIELD1": 90,
      "FIELD2": 90,
      "Gene name": "AKT1",
      "Genomic Position": "14:105235686-105260461(-)",
      "CDS Mutation": "c.49G>A",
      "AA Mutation": "p.E17K",
      "Disease": "Breast Cancer",
      "therapy_rank": 4,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capivasertib",
      "Description": "",
      "rs value": 121434592,
      "pmid": "PubMed:26351323"
    },
    {
      "FIELD1": 91,
      "FIELD2": 91,
      "Gene name": "BRCA2",
      "Genomic Position": "13:32889617-32973805(+)",
      "CDS Mutation": "unspecified_and_ERBB2_unspecified",
      "AA Mutation": "unspecified_and_ERBB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 92,
      "FIELD2": 92,
      "Gene name": "BRCA2",
      "Genomic Position": "13:32889617-32973805(+)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Triple-receptor Negative Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 93,
      "FIELD2": 93,
      "Gene name": "BRCA2",
      "Genomic Position": "13:32889617-32973805(+)",
      "CDS Mutation": "Loss-of-function",
      "AA Mutation": "Loss-of-function",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 94,
      "FIELD2": 94,
      "Gene name": "BRCA2",
      "Genomic Position": "13:32889617-32973805(+)",
      "CDS Mutation": "Loss-of-function",
      "AA Mutation": "Loss-of-function",
      "Disease": "Her2-receptor Negative Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 95,
      "FIELD2": 95,
      "Gene name": "BRCA2",
      "Genomic Position": "13:32889617-32973805(+)",
      "CDS Mutation": "Mutation",
      "AA Mutation": "Mutation",
      "Disease": "Breast Cancer",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 96,
      "FIELD2": 96,
      "Gene name": "BRCA2",
      "Genomic Position": "13:32889617-32973805(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 97,
      "FIELD2": 97,
      "Gene name": "ETV6",
      "Genomic Position": "12:11802788-12048336(+)",
      "CDS Mutation": "ETV6::NTRK3",
      "AA Mutation": "p.ETV6::NTRK3",
      "Disease": "Breast Secretory Carcinoma",
      "therapy_rank": 4,
      "Response to Drug": "Sensitivity",
      "Therapies": "Larotrectinib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:29623306"
    },
    {
      "FIELD1": 98,
      "FIELD2": 98,
      "Gene name": "CDKN2A",
      "Genomic Position": "9:21968055-21974865(-)",
      "CDS Mutation": "Loss",
      "AA Mutation": "Loss",
      "Disease": "Her2-receptor Negative Breast Cancer",
      "therapy_rank": 4,
      "Response to Drug": "Sensitivity",
      "Therapies": "Letrozole,Palbociclib",
      "Description": "",
      "rs value": null,
      "pmid": "PubMed:26715889"
    },
    {
      "FIELD1": 99,
      "FIELD2": 99,
      "Gene name": "BARD1",
      "Genomic Position": "2:215590370-215674428(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Talazoparib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04892693"
    },
    {
      "FIELD1": 100,
      "FIELD2": 100,
      "Gene name": "PPP2R2A",
      "Genomic Position": "8:26150732-26228402(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Talazoparib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04892693"
    },
    {
      "FIELD1": 101,
      "FIELD2": 101,
      "Gene name": "ERBB3",
      "Genomic Position": "12:56473645-56497289(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Patritumab deruxtecan",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02980341"
    },
    {
      "FIELD1": 102,
      "FIELD2": 102,
      "Gene name": "CHEK2",
      "Genomic Position": "22:29083751-29137826(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 103,
      "FIELD2": 103,
      "Gene name": "EGFR",
      "Genomic Position": "7:55086794-55279321(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Gefitinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT01732276"
    },
    {
      "FIELD1": 104,
      "FIELD2": 104,
      "Gene name": "EGFR",
      "Genomic Position": "7:55086794-55279321(+)",
      "CDS Mutation": "unspecified_and_ERBB2_unspecified",
      "AA Mutation": "unspecified_and_ERBB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Gefitinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT01732276"
    },
    {
      "FIELD1": 105,
      "FIELD2": 105,
      "Gene name": "EGFR",
      "Genomic Position": "7:55086794-55279321(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Gefitinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT01732276"
    },
    {
      "FIELD1": 106,
      "FIELD2": 106,
      "Gene name": "EGFR",
      "Genomic Position": "7:55086794-55279321(+)",
      "CDS Mutation": "unspecified_or_ERBB2_unspecified",
      "AA Mutation": "unspecified_or_ERBB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Gefitinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT01732276"
    },
    {
      "FIELD1": 107,
      "FIELD2": 107,
      "Gene name": "EGFR",
      "Genomic Position": "7:55086794-55279321(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Gefitinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT01732276"
    },
    {
      "FIELD1": 108,
      "FIELD2": 108,
      "Gene name": "ERBB4",
      "Genomic Position": "2:212240446-213403565(-)",
      "CDS Mutation": "unspecified_and_CD274_unspecified",
      "AA Mutation": "unspecified_and_CD274_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04872985"
    },
    {
      "FIELD1": 109,
      "FIELD2": 109,
      "Gene name": "ERBB4",
      "Genomic Position": "2:212240446-213403565(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04872985"
    },
    {
      "FIELD1": 110,
      "FIELD2": 110,
      "Gene name": "ERBB4",
      "Genomic Position": "2:212240446-213403565(-)",
      "CDS Mutation": "unspecified_and_CD274_unspecified",
      "AA Mutation": "unspecified_and_CD274_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04872985"
    },
    {
      "FIELD1": 111,
      "FIELD2": 111,
      "Gene name": "FGFR3",
      "Genomic Position": "4:1795039-1810599(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Futibatinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04024436"
    },
    {
      "FIELD1": 112,
      "FIELD2": 112,
      "Gene name": "BCL2",
      "Genomic Position": "18:60790579-60987361(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Letrozole + Palbociclib + Venetoclax",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT03900884"
    },
    {
      "FIELD1": 113,
      "FIELD2": 113,
      "Gene name": "ALK",
      "Genomic Position": "2:29415640-30144432(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Crizotinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02034981"
    },
    {
      "FIELD1": 114,
      "FIELD2": 114,
      "Gene name": "CDK12",
      "Genomic Position": "17:37618292-37691399(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Talazoparib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04892693"
    },
    {
      "FIELD1": 115,
      "FIELD2": 115,
      "Gene name": "MTOR",
      "Genomic Position": "1:11166592-11322564(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Vistusertib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02299999"
    },
    {
      "FIELD1": 116,
      "FIELD2": 116,
      "Gene name": "CD274",
      "Genomic Position": "9:5450525-5470547(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Avelumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02926196"
    },
    {
      "FIELD1": 117,
      "FIELD2": 117,
      "Gene name": "CD274",
      "Genomic Position": "9:5450525-5470547(+)",
      "CDS Mutation": "unspecified_and_ERBB2_unspecified",
      "AA Mutation": "unspecified_and_ERBB2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Avelumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02926196"
    },
    {
      "FIELD1": 118,
      "FIELD2": 118,
      "Gene name": "CD274",
      "Genomic Position": "9:5450525-5470547(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Avelumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02926196"
    },
    {
      "FIELD1": 119,
      "FIELD2": 119,
      "Gene name": "CD274",
      "Genomic Position": "9:5450525-5470547(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Avelumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02926196"
    },
    {
      "FIELD1": 120,
      "FIELD2": 120,
      "Gene name": "CD274",
      "Genomic Position": "9:5450525-5470547(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Avelumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT02926196"
    },
    {
      "FIELD1": 121,
      "FIELD2": 121,
      "Gene name": "RET",
      "Genomic Position": "10:43572475-43625799(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Lenvatinib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT03168074"
    },
    {
      "FIELD1": 122,
      "FIELD2": 122,
      "Gene name": "RAD51D",
      "Genomic Position": "17:33427691-33446832(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    },
    {
      "FIELD1": 123,
      "FIELD2": 123,
      "Gene name": "ROS1",
      "Genomic Position": "6:117609463-117747018(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Crizotinib + Fulvestrant",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT03620643"
    },
    {
      "FIELD1": 124,
      "FIELD2": 124,
      "Gene name": "NF1",
      "Genomic Position": "17:29421945-29704695(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Famitinib + SHR7390",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04355858"
    },
    {
      "FIELD1": 125,
      "FIELD2": 125,
      "Gene name": "KRAS",
      "Genomic Position": "12:25362365-25403737(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Paclitaxel + Pelareorep",
      "Description": "",
      "rs value": null,
      "pmid": "Corporate website:NCT01656538"
    },
    {
      "FIELD1": 126,
      "FIELD2": 126,
      "Gene name": "KRAS",
      "Genomic Position": "12:25362365-25403737(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Paclitaxel + Pelareorep",
      "Description": "",
      "rs value": null,
      "pmid": "Corporate website:NCT01656538"
    },
    {
      "FIELD1": 127,
      "FIELD2": 127,
      "Gene name": "PDGFRB",
      "Genomic Position": "5:149493400-149535423(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Famitinb",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04355858"
    },
    {
      "FIELD1": 128,
      "FIELD2": 128,
      "Gene name": "BRIP1",
      "Genomic Position": "17:59758627-59940882(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Talazoparib",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04892693"
    },
    {
      "FIELD1": 129,
      "FIELD2": 129,
      "Gene name": "ATM",
      "Genomic Position": "11:108093559-108239826(+)",
      "CDS Mutation": "unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
      "AA Mutation": "unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 1,
      "Response to Drug": "Sensitivity",
      "Therapies": "Olaparib + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05033756"
    },
    {
      "FIELD1": 130,
      "FIELD2": 130,
      "Gene name": "ATM",
      "Genomic Position": "11:108093559-108239826(+)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Olaparib + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05033756"
    },
    {
      "FIELD1": 131,
      "FIELD2": 131,
      "Gene name": "ATM",
      "Genomic Position": "11:108093559-108239826(+)",
      "CDS Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
      "AA Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Olaparib + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05033756"
    },
    {
      "FIELD1": 132,
      "FIELD2": 132,
      "Gene name": "ATM",
      "Genomic Position": "11:108093559-108239826(+)",
      "CDS Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
      "AA Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Olaparib + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05033756"
    },
    {
      "FIELD1": 133,
      "FIELD2": 133,
      "Gene name": "ATM",
      "Genomic Position": "11:108093559-108239826(+)",
      "CDS Mutation": "unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
      "AA Mutation": "unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Olaparib + Pembrolizumab",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT05033756"
    },
    {
      "FIELD1": 134,
      "FIELD2": 134,
      "Gene name": "PALB2",
      "Genomic Position": "16:23614491-23652631(-)",
      "CDS Mutation": "unspecified",
      "AA Mutation": "unspecified",
      "Disease": "breast / carcinoma / NS",
      "therapy_rank": 3,
      "Response to Drug": "Sensitivity",
      "Therapies": "Capecitabine + Platinum-based chemotherapy",
      "Description": "",
      "rs value": null,
      "pmid": "ClinicalTrials.gov:NCT04335669"
    }
   ]